Operating expenses - Narrative (Details) - EUR (€) € in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Research and development expenses | ||
| Disclosure of attribution of expenses by nature to their function [line items] | ||
| Increase (decrease) in Ulcerative Colitis expenses | € 1,587 | € 32,030 |
| Increase (decrease) in Crohn's Disease research expenses | 10,200 | 4,620 |
| Increase (decrease) in transversal activities | 12,987 | € 8,233 |
| Increase (decrease) in transversal activities, combination therapy | 4,122 | |
| Increase (decrease) in employer tax and social contributions | 20,131 | |
| General and administrative expense | ||
| Disclosure of attribution of expenses by nature to their function [line items] | ||
| Increase (decrease) in employer tax and social contributions | € 27,299 | |